HLVX RSI Chart
Last 7 days
11.1%
Last 30 days
19.5%
Last 90 days
1.4%
Trailing 12 Months
5.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 03, 2024 | kohli aditya | sold | -10,233 | 14.1542 | -723 | - |
May 02, 2024 | kohli aditya | sold | -84,081 | 14.0135 | -6,000 | - |
May 01, 2024 | kohli aditya | sold | -2,456 | 14.0343 | -175 | - |
Apr 05, 2024 | kohli aditya | sold | -86,640 | 14.44 | -6,000 | - |
Apr 04, 2024 | frazier life sciences x, l.p. | bought | 128,325 | 14.5 | 8,850 | - |
Apr 04, 2024 | kohli aditya | sold | -88,245 | 14.7075 | -6,000 | - |
Apr 03, 2024 | kohli aditya | sold | -89,581 | 14.9303 | -6,000 | - |
Mar 28, 2024 | mcloughlin sean | bought | 21,225 | 16.98 | 1,250 | chief operating officer |
Mar 20, 2024 | kohli aditya | sold | -985,326,000 | 164,221 | -6,000 | - |
Mar 19, 2024 | kohli aditya | sold | -104,492 | 17.4153 | -6,000 | - |
Which funds bought or sold HLVX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Tudor Investment Corp Et Al | unchanged | - | 10,280 | 294,750 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -77.81 | -30,355 | 9,063 | -% |
May 15, 2024 | Woodline Partners LP | new | - | 315,804 | 315,804 | -% |
May 15, 2024 | ACUTA CAPITAL PARTNERS, LLC | reduced | -22.79 | -1,042,200 | 4,167,630 | 2.71% |
May 15, 2024 | Deep Track Capital, LP | reduced | -11.29 | -3,764,990 | 42,780,000 | 1.23% |
May 15, 2024 | Frazier Life Sciences Management, L.P. | unchanged | - | 5,673,250 | 162,666,000 | 6.86% |
May 15, 2024 | T. Rowe Price Investment Management, Inc. | added | 110 | 27,583,000 | 50,917,000 | 0.03% |
May 15, 2024 | BRAIDWELL LP | sold off | -100 | -3,264,680 | - | -% |
May 15, 2024 | VR Adviser, LLC | unchanged | - | 1,203,500 | 34,507,200 | 1.64% |
May 15, 2024 | D. E. Shaw & Co., Inc. | new | - | 468,284 | 468,284 | -% |
Unveiling HilleVax, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
HilleVax, Inc. News
Balance Sheet | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -8.8% | 314 | 344 | 367 | 287 | 301 | 317 | 322 | 341 | 115 | 127 |
Current Assets | -9.5% | 281 | 311 | 333 | 253 | 270 | 291 | 300 | 320 | 112 | 125 |
Cash Equivalents | -34.9% | 141 | 217 | 209 | 158 | 261 | 279 | 292 | 315 | 111 | 125 |
Net PPE | -3.0% | 14.00 | 14.00 | 14.00 | 13.00 | 10.00 | 6.00 | 1.00 | - | - | 0.00 |
Liabilities | -4.6% | 75.00 | 79.00 | 68.00 | 68.00 | 58.00 | 50.00 | 35.00 | 38.00 | 283 | 228 |
Current Liabilities | -12.0% | 26.00 | 29.00 | 19.00 | 18.00 | 19.00 | 13.00 | 9.00 | 13.00 | 283 | 228 |
Long Term Debt | 0.8% | 25.00 | 25.00 | 25.00 | 25.00 | 15.00 | 15.00 | 5.00 | 5.00 | - | - |
LT Debt, Non Current | -100.0% | - | 25.00 | 25.00 | 25.00 | 15.00 | 15.00 | 5.00 | 5.00 | - | - |
Shareholder's Equity | -10.0% | 239 | 266 | 299 | 219 | 243 | 267 | 287 | 303 | - | -100 |
Retained Earnings | -12.1% | -435 | -388 | -351 | -319 | -291 | -264 | -243 | -227 | -173 | -105 |
Additional Paid-In Capital | 3.1% | 675 | 655 | 651 | 539 | 535 | 532 | 531 | 530 | 5.00 | 4.00 |
Shares Outstanding | 2.9% | 49.00 | 48.00 | 47.00 | 38.00 | 38.00 | 38.00 | 24.00 | 27.00 | 7.00 | 7.00 |
Float | - | - | - | - | 258 | - | - | - | 228 | - | - |
Cashflow (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Cashflow From Operations | -52.7% | -33,002 | -21,606 | -26,806 | -22,417 | -15,954 | -18,517 | -19,547 | -13,210 | -10,715 | -4,194 | -1,565 | -1,119 | -417 |
Share Based Compensation | 38.3% | 5,194 | 3,756 | 3,946 | 3,246 | 2,642 | 1,331 | 844 | 556 | 272 | - | - | - | - |
Cashflow From Investing | -295.7% | -57,662 | 29,469 | -31,174 | -89,948 | -2,985 | -3,829 | -185 | - | -2,500 | - | - | - | - |
Cashflow From Financing | 4712.1% | 15,062 | 313 | 108,107 | 10,198 | 80.00 | 9,687 | -2,820 | 218,201 | -99.00 | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development (includes related party amounts of $27 and $168, respectively) | $ 25,978 | $ 23,164 |
In-process research and development | 15,325 | |
General and administrative (includes related party amounts of $0 and $3, respectively) | 8,494 | 5,795 |
Total operating expenses | 49,797 | 28,959 |
Loss from operations | (49,797) | (28,959) |
Other income (expense): | ||
Interest income | 2,402 | 2,574 |
Interest expense | (727) | (449) |
Other income (expense) | 1,293 | (55) |
Total other income | 2,968 | 2,070 |
Net loss | (46,829) | (26,889) |
Other comprehensive income (loss): | ||
Unrealized loss on marketable securities | (121) | |
Pension and other postemployment benefits | 78 | (1) |
Total comprehensive loss | $ (46,872) | $ (26,890) |
Net loss per share, basic | $ (0.97) | $ (0.71) |
Net loss per share, diluted | $ (0.97) | $ (0.71) |
Weighted-average shares of common stock outstanding, basic | 48,460,185 | 37,753,522 |
Weighted-average shares of common stock outstanding, diluted | 48,460,185 | 37,753,522 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 141,076 | $ 216,678 |
Marketable securities | 131,667 | 86,805 |
Prepaid expenses and other current assets (includes related party amounts of $77 and $0, respectively) | 8,355 | 7,195 |
Total current assets | 281,098 | 310,678 |
Property and equipment, net | 13,592 | 14,018 |
Operating lease right-of-use assets | 17,831 | 18,082 |
Restricted cash | 1,631 | 1,631 |
Other assets | 23 | 25 |
Total assets | 314,175 | 344,434 |
Current liabilities: | ||
Accounts payable | 2,980 | 7,461 |
Accrued expenses (includes related party amounts of $27 and $33, respectively) | 19,143 | 18,553 |
Accrued interest | 135 | 134 |
Current portion of operating lease liability | 3,491 | 3,118 |
Total current liabilities | 25,749 | 29,266 |
Operating lease liability, net of current portion | 22,364 | 22,831 |
Long-term debt, net of debt discount | 25,453 | 25,244 |
Other long-term liabilities | 1,700 | 1,568 |
Total liabilities | 75,266 | 78,909 |
Commitments and contingencies (Note 8) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; authorized shares- 50,000,000 at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock, $0.0001 par value; authorized shares-500,000,000 at March 31, 2024 and December 31, 2023; issued shares- 49,718,443 and 48,497,853 at March 31, 2024 and December 31, 2023, respectively; outstanding shares-49,055,192 and 47,666,438 at March 31, 2024 and December 31, 2023, respectively | 5 | 5 |
Additional paid-in capital | 675,242 | 654,986 |
Accumulated other comprehensive loss | (950) | (907) |
Accumulated deficit | (435,388) | (388,559) |
Total stockholders' equity | 238,909 | 265,525 |
Total liabilities and stockholders' equity | $ 314,175 | $ 344,434 |